Study on the Biological Distribution of ENO1 mAb in Cervical Cancer Bearing Mice Monitored by Near Infrared Fluorescence Imaging

doi:10.7517/issn.1674-0475.230808

Abstract

Abstract: In this study, the distribution, metabolism and tumor targeting efficiency of Enolase 1 (ENO1) monoclonal antibody (mAb) in cervical cancer bearing mice were investigated by near infrared fluorescence imaging. The relationship between ENO1 expression and tumor stage, prognosis and tumor immune invasion was analyzed by cancer genome atlas. Cy7-NHS and FITC were coupled with ENO1 mAb to form Cy7-ENO1 mAb and FITC-ENO1 mAb, and the localization of ENO1 mAb in cervical cancer cell TC-1 was verified by laser confocal microscopy, and the subcutaneous tumor model of cervical cancer was established. Near infrared fluorescence (NIRF) imaging was performed at 1, 6, 24, 48, 72, and 120 h after caudal intravenous injection of Cy7-ENO1 mAb. After 24 h of imaging, major organs were rapidly dissected for in vitro imaging. Bioinformatics results showed significant differences in the expression of ENO1 between normal cervical tissue and cervical cancer tissue while immunohistochemistry (IHC) indicated higher ENO1 protein expression in cervical cancer tissues. In addition, the expression of ENO1 was significantly correlated with tumor stage and lymph node stage, and the high expression of ENO1 was correlated with multiple glycolytic enzymes. Confocal laser microscopy showed that FITC-ENO1 mAb could specifically bind to the surface of TC-1 cell membrane, and no cell internalization was observed. Near infrared fluorescence imaging showed that Cy7-ENO1 mAb was mainly enriched in liver, kidney and tumor tissues, and had high tumor targeting efficiency. NIRF imaging allows real-time and dynamic monitoring of ENO1 mAb distribution in cervical cancer bearing mice, whose metabolic organs are mainly liver and kidney, and confirms ENO1 mAb's targeting of cervical cancer.

Key words: near infrared fluorescence imaging, ENO1 mAb, biodistribution, Cy7-NHS

ZHAO Tiaohong, ZHANG Tingting, CHEN Yuanyuan, LU Ruxia, ZHAO Yuanxu, PEI Yaping, LIU Huiling, ZHU Bingdong. Study on the Biological Distribution of ENO1 mAb in Cervical Cancer Bearing Mice Monitored by Near Infrared Fluorescence Imaging[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2023, 41(6): 350-357.

References

[1] Zuo J H, Wang B W, Long M, et al. The type 1 transmembrane glycoprotein B7-H3 interacts with the glycolytic enzyme ENO1 to promote malignancy and glycolysis in HeLa cells[J]. FEBS Letters, 2018, 592(14):2476-2488.
[2] Dammes N, Peer D. Monoclonal antibody-based molecular imaging strategies and theranostic opportunities[J]. Theranostics, 2020, 10(2):938-955.
[3] Lin M, Paolillo V, Le D B, et al. Monoclonal antibody based radiopharmaceuticals for imaging and therapy[J]. Current Problems in Cancer, 2021, 45(5):100796.
[4] 张胜华, 程昕, 钟根深,等. 活体成像分析异硫氰酸荧光素标记Rituximab在荷淋巴瘤裸鼠体内的生物分布[J]. 中华医学杂志, 2010, 90(33):2367-2370.
[5] Gou Y F, Li F, Huo X Q, et al. ENO1 monoclonal antibody inhibits invasion, proliferation and clone formation of cervical cancer cells[J]. American Journal of Cancer Research, 2021, 11(5):1946-1961.
[6] Zhang C, Ling X Y, Guo Y X, et al. Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging[J]. Chinese Journal of Cancer Research, 2019, 31(4):673-685.
[7] Siegel R L, Miller K D, Fuchs H E, et al. Cancer Statistics, 2021[J]. CA:A Cancer Journal For Clinicians, 2021, 71(1):7-33.
[8] Arbyn M, Weideprass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018:A worldwide analysis[J]. The Lancet Global Health, 2020, 8(2):e191-e203.
[9] Liang Y K, Wang H, Chen B, et al. circDCUN1D4 suppresses tumor metastasis and glycolysis in lung adenocarcinoma by stabilizing TXNIP expression[J]. Molecular Therapy-Nucleic Acids, 2021, 23:355-368.
[10] Sedoris K C, Thomas S D, Miller D M. C-myc promoter binding protein regulates the cellular response to an altered glucose concentration[J]. Biochemistry, 2007, 46(29):8659-8668.
[11] Kang M, Abdelmageed H, Lee S, et al. AtMBP-1, an alternative translation product of LOS2, affects abscisic acid responses and is modulated by the E3 ubiquitin ligase AtSAP5[J]. The Plant Journal:for Cell and Molecular Biology, 2013, 76(3):481-493.
[12] Principe M, Borgoni S, Cascione M, et al. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis[J]. Journal of Hematology & Oncology, 2017, 10(1):16.
[13] Yin H, Wang L, Liu H L. ENO1 overexpression in pancreatic cancer patients and its clinical and diagnostic significance[J]. Gastroenterology Research and Practice, 2018, 2018:3842198.
[14] Zhan P P, Wang Y L, Zhao S H, et al. FBXW7 negatively regulates ENO1 expression and function in colorectal cancer[J]. Laboratory Investigation, 2015, 95(9):995-1004.
[15] Expression of Concern:Up-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating β-catenin[J].Bioscience Reports, 2021, 41(2):BSR20190503.
[16] Zhang L H, Wang H B, Dong X J. Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer [J]. Jornal Brasileiro de Pneumologia, 2018, 44(1):18-23.
[17] Qiao H, Wang Y F, Yuan W Z, et al. Silencing of ENO1 by shRNA inhibits the proliferation of gastric cancer cells[J]. Technology in Cancer Research Treatment, 2018, 17:153303381878441.
[18] Hoang A T, Vizio B, Chiusa L, et al. Impact of tissue enolase 1 protein overexpression in esophageal cancer progression[J]. International Journal of Medical Sciences, 2021, 18(6):1406-1414.
[19] Tang B, Cui L J, Xu K H, et al. A sensitive and selective near-infrared fluorescent probe for mercuric ions and its biological imaging applications[J]. ChemBioChem, 2008, 9(7):1159-1164.
[20] Cheson B D, Leonard J P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma[J]. New England Journal of Medicine, 2008, 359(6):613-626.